CTOs on the Move

Osco Drug

www.oscodrug.com

 
Osco Drug is a Springfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.oscodrug.com
  • 1901 W Monroe St
    Springfield, IL USA 62704
  • Phone: 217.787.2830

Executives

Name Title Contact Details

Similar Companies

GW Pharmaceuticals

GW was co-founded in 1998 by Dr. Geoffrey Guy and Dr. Brian Whittle, two well-known entrepreneurs in the UK biotech sector. In setting up GW, Drs. Guy and Whittle worked closely with both the UK Home Office and the UK`s medicines regulatory authority on establishing necessary licences and procedures so as to facilitate the progress of GW`s cannabinoid research program.

MiddleBrook Pharmaceuticals

MiddleBrook Pharmaceuticals, Inc. is a Westlake, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vidantus Alliance

Vidantus Alliance is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sunrise Pharmaceutical Inc

Sunrise Pharmaceutical Inc is a Rahway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.